GI Dynamics (ASX:GID) said a retrospective study of its EndoBarrier device for patients with type 2 diabetes and obesity shows a significant reduction in HbA1c, weight, liver fat and cardiovascular disease (CVD) risks as well as a reduction in the need for insulin in some patients.
The EndoBarrier device is a plastic gut sleeve designed to prevent the absorption of nutrients from food as it exits the stomach and enters the intestinal tract, according to the Lexington, Mass.-based company.
Get the full story on our sister site, Medical Design & Outsourcing.
The post GI Dynamics touts results of U.K. study appeared first on MassDevice.
from MassDevice https://ift.tt/2TUDpcc
Cap comentari:
Publica un comentari a l'entrada